ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2906

Systemic Delivery of Short Hairpin RNA Targeting Calcium Release-Activated Calcium Channel 3 Down-Regulates Severity of Collagen-Induced Arthritis

Shuang Liu1, Takeshi Kiyoi2, Shohei Watanabe3 and Kazutaka Maeyama1, 1Department of Pharmacology, Informational Biomedicine, Ehime University Graduate School of Medicine, Toon-shi, Ehime, Japan, 2Bioscience, Integrated Center for Sciences, Ehime University, Ehime, Japan, 3Japan Community Health Care Organization Uwajima Hospital, Ehime, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Arthritis, Calcium, Inflammation and osteoclasts

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Animal Models II

Session Type: Abstract Submissions (ACR)

Background/Purpose: In recent years, one widespread and potentially important Ca2+ channel, store-operated Ca2+-release-activated Ca2+ (CRAC) channel is raised in drug discovery for rheumatoid arthritis (RA). Ca2+ entry through CRAC channels drives exocytosis, stimulates mitochondrial metabolism, activates gene expression and promote cell growth and proliferation in non-exitable cells. Downregulation of the CRAC channels lead to irregular functions of T cells, B cells and osteoclasts, which contribute to RA pathogenesis. The present study was undertaken to investigate the feasibility and efficiency of partially regulation of the Ca2+ influx via CRAC channel by CRACM3 gene-silencing for the treatment of RA.

Methods: We evaluated the therapeutic potential of CRACM3 gene-silencing by systemic delivery of lentivirus expressing CRACM3-shRNA (Lenti-M3shRNA) in a collagen-induced arthritis (CIA) mouse model. The inflammatory response was assessed by measuring the levels of inflammatory cytokines in joint and serum. The cytokine profile of T cells stimulated with autoantigen was also determined. Mature osteoclast function was analyzed using tartrate-resistant acid phosphatase (TRAP) staining and pit formation assay.

Results: The intraperitoneal injection (109 particles/7 days) of Lenti-M3shRNA was highly effective in treating CIA. Ca2+ influxes in splenocytes, thymocytes, and synovial cells were partially blocked by gene-silencing of CRACM3. CIA mice showed significant regression of the disease after Lenti-M3shRNA treatment. The autoimmune response, which was assessed using self-reactive Th1 cell activity and autoantibody production, was significantly suppressed by M3shRNA administration. Low level of the resorptive capacity in mature osteoclasts was also observed in Lenti-M3shRNA treated CIA mice according to the results of TRAP staining and pit formation assay.

Conclusion: Our findings indicate that in vivo gene-silencing CRACM3 by systemic delivery of Lenti-M3shRNA may have beneficial therapeutic effects on RA. Our findings provide valuable insight into the potential ways that CRACMs could contribute to RA pathogenesis and support the idea that targeting CRAC channels might offer an effective strategy for the treatment of RA.


Disclosure:

S. Liu,
None;

T. Kiyoi,
None;

S. Watanabe,
None;

K. Maeyama,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systemic-delivery-of-short-hairpin-rna-targeting-calcium-release-activated-calcium-channel-3-down-regulates-severity-of-collagen-induced-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology